Zydus Therapeutics Reports Positive Phase 2b Trial Data for Saroglitazar in MASH
Zydus Lifesciences Ltd 路 Press Release 路 07 Nov 2026, 12:27 am
Zydus Therapeutics Reports Positive Phase 2b Trial Data for Saroglitazar in MASH On 6th Nov'26, Zydus Therapeutics reported Phase 2b EVIDENCES X trial results for saroglitazar in adults with MASH and F2鈥揊3 fibrosis. The 52-week study met its primary endpoint: steatohepatitis resolution without fibrosis worsening was achieved by 39.1% on 4 mg (P=0.002) and 32.4% on 2 mg (P=0.033), versus 13.7% for placebo. Fibrosis improvement without NAS worsening was 34.8% (4 mg) versus 24.6% (placebo). Saroglitazar was well tolerated without significant weight gain or drug-induced liver injury, showing favorable non-invasive liver fibrosis biomarker improvements.
Original exchange filing (PDF)
More announcements from Zydus Lifesciences Ltd
- Press Release 路 14 Nov 2026
- Completion of transaction 路 12 Nov 2026
- Transcript of the post results earnings call held on November 4, 2026. 路 07 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India 路 06 Nov 2026
- Investor Conference 路 06 Nov 2026
- Audio recording of the Company's Investor Call 路 05 Nov 2026
- Press Release 路 04 Nov 2026
- Investor presentation 路 04 Nov 2026
